HALEOS LABS LIMITED has informed the Exchange about Credit Rating
HALEOSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Infomerics has reaffirmed credit ratings for HALEOS LABS LIMITED and its material subsidiary Mahi Drugs Private Limited. For the parent company, long-term rating stays at IVR BBB/Positive and short-term at IVR A3+, while total bank loan facilities increased to Rs. 116.01 crore from Rs. 81.86 crore. The subsidiary Mahi Drugs maintains IVR BB+/Stable rating with facilities enhanced to Rs. 20.75 crore from Rs. 10.83 crore. The reaffirmation reflects review of the company's operational and financial performance for FY25 and 9MFY26. The Positive outlook on the parent indicates potential for future upgrade.
The reaffirmation of investment-grade ratings with a positive outlook is a vote of confidence in the company's creditworthiness. The increased borrowing limits suggest the company is scaling up its debt facilities, possibly to fund growth plans. For shareholders, this indicates healthy financial standing and continued lender confidence in both entities.